sur le Forfait Innovation pour le traitement des patients atteints de glioblastome récurrent.
CARTHERA RECEIVES POSITIVE OPINION FROM FRENCH HIGH AUTHORITY FOR HEALTH ON INNOVATION FUNDING SCHEME TO TREAT PATIENTS WITH RECURRENT GLIOBLASTOMA
Following positive opinion, ultrasound-based medical device company will obtain temporary funding to conduct first registrational trial of SonoCloud® device in France
Paris, France, July 1, 2024 – Carthera,a spin-off from Sorbonne University founded by Pr. Alexandre Carpentier, and developer of SonoCloud®, an innovative ultrasound-based medical device to treat a wide range of brain disorders, today announces that HAS, the French High Authority for Health, has issued a positive opinion on taking over the costs associated with the SonoCloud-9 system in the SONOBIRD study, within the framework of the Forfait Innovation (Innovation Funding) program.